Alnylam Pharmaceuticals, Inc. (ALNY) vs BioNTech SE (BNTX)
A side-by-side comparison of Alnylam Pharmaceuticals, Inc. and BioNTech SE across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 23, 2026. Differences are shown without an overall score or investment verdict.
ALNY
Alnylam Pharmaceuticals, Inc.
$236.22HealthcareAt close: Aug 21, 2026, 4:00 PM ET
BNTX
BioNTech SE
$116.57HealthcareAt close: Aug 21, 2026, 4:00 PM ET
Total return — ALNY vs BNTX
growth of $100 · dividends reinvested · last 7yALNY +206.7% (+17.4%/yr)BNTX +729.5% (+35.3%/yr)BNTX compounded faster over this window
ALNY BNTX
ALNY vs BNTX: by the numbers
- •ALNY is the larger company ($31.61B vs $29.28B market cap).
- •ALNY is profitable (16.82% net margin) while BNTX runs a net loss (-62.98%).
- •ALNY grew revenue faster over the past five years (47.53% vs 40.61% CAGR).
Metrics side by side
Valuation
| Metric | ALNY | BNTX |
|---|---|---|
| P/E ratio | 39.90 | N/A |
| Forward P/E | 36.30 | N/A |
| P/S ratio | 6.80 | 9.53 |
| P/B ratio | 24.12 | 1.46 |
| EV / EBITDA | 30.56 | N/A |
| FCF yield | 1.66% | 2.10% |
Profitability
| Metric | ALNY | BNTX |
|---|---|---|
| Gross margin | 79.72% | 70.98% |
| Operating margin | 20.81% | -22.63% |
| Net margin | 16.82% | -62.98% |
| ROE | 59.67% | -9.62% |
| ROIC | 24.71% | -10.37% |
Growth (annualized)
| Metric | ALNY | BNTX |
|---|---|---|
| Revenue CAGR (5Y) | 47.53% | 40.61% |
| Total return CAGR (5Y) | 3.61% | -19.46% |
Frequently asked
- Which has grown faster, ALNY or BNTX?
- Over the past five years, ALNY grew revenue faster — ALNY at a 47.53% CAGR versus BNTX at 40.61%.
- Is ALNY or BNTX more profitable?
- ALNY runs the higher net margin — ALNY at 16.82% versus BNTX at -62.98%.
- How have ALNY and BNTX total returns compared?
- Over the past 5 years, ALNY delivered 12.49% and BNTX delivered -19.46% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Alnylam Pharmaceuticals P/E ratioAlnylam Pharmaceuticals ROEBioNTech SE ROEAlnylam Pharmaceuticals operating marginBioNTech SE operating marginAlnylam Pharmaceuticals revenue growthBioNTech SE revenue growthAlnylam Pharmaceuticals free cash flowBioNTech SE free cash flow
Alnylam Pharmaceuticals & BioNTech SE appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 23, 2026.